Selective optimization of side activities: the SOSA approach.

[1]  C. Wermuth,et al.  SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome , 2005, Psychopharmacology.

[2]  W. Humphreys,et al.  Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. , 2004, Journal of medicinal chemistry.

[3]  R. Silvestri,et al.  Imidazole analogues of fluoxetine, a novel class of anti-Candida agents. , 2004, Journal of medicinal chemistry.

[4]  C. Wermuth.  Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.

[5]  J. Greer,et al.  Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues. , 2004, Journal of medicinal chemistry.

[6]  P. Worms,et al.  Dopamine-like activities of an aminopyridazine derivative, CM 30366: A behavioural study , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  G. Forloni,et al.  Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat , 2004, Psychopharmacology.

[8]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[9]  Christel A. S. Bergström,et al.  Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.

[10]  Ping Chen,et al.  Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. , 2003, Journal of medicinal chemistry.

[11]  André Mann,et al.  Nouveaux ligands des récepteurs dopaminergiques D3 , 2003 .

[12]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[13]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[14]  J. Kelly,et al.  Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. , 2002, Journal of medicinal chemistry.

[15]  C. Wermuth,et al.  Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors. , 2001, Journal of medicinal chemistry.

[16]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[17]  C. Wermuth.  The Sosa approach: An alternative to high-throughput screening , 2001 .

[18]  B. Lagu.  Identification of alpha1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia , 2001 .

[19]  U. Gerlach.  IKs channel blockers: Potential antiarrhythmic agents , 2001 .

[20]  A. Doherty,et al.  Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. , 2000, Journal of medicinal chemistry.

[21]  T. Raju.  The Nobel Chronicles , 2000, The Lancet.

[22]  Kleeman Hw,et al.  Recent developments in the field of inhibitors of the Na+/H+ exchanger. , 1999 .

[23]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[24]  C. Wermuth,et al.  Aminopyridazines as acetylcholinesterase inhibitors. , 1999, Journal of medicinal chemistry.

[25]  C. Wermuth.  Search for new lead compounds: The example of the chemical and pharmacological dissection of aminopyridazines , 1998 .

[26]  Scott A. Peterson,et al.  Discovering transthyretin amyloid fibril inhibitors by limited screening. , 1998, Bioorganic & medicinal chemistry.

[27]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[28]  H. Böhm,et al.  Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. , 1996, Journal of medicinal chemistry.

[29]  Y. Shu,et al.  BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. I. Taxonomy, fermentation, isolation and biological activity. , 1995, The Journal of antibiotics.

[30]  Y. Shu,et al.  BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. II. Physico-chemical properties and structural characterization. , 1995, The Journal of antibiotics.

[31]  N. Murugesan,et al.  The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. , 1994, Journal of medicinal chemistry.

[32]  P. Soubrié,et al.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Wermuth,et al.  SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome , 1992 .

[34]  C. Wermuth,et al.  3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities. , 1989, Journal of medicinal chemistry.

[35]  D. Cucinotta,et al.  Comparison of minaprine and placebo in the treatment of Alzheimer's disease and multi‐infarct dementia , 1987 .

[36]  C. Wermuth,et al.  SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. , 1987, The Journal of pharmacology and experimental therapeutics.

[37]  C. Wermuth,et al.  Profil pharmacologique d'un psychotrope original, la minaprine: comparaison avec six antidépresseurs de référence , 1986 .

[38]  L. Sternbach.  The benzodiazepine story. , 1983, Journal of psychoactive drugs.

[39]  J. Kan,et al.  Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug. , 1982, Arzneimittel-Forschung.

[40]  R. Roncucci,et al.  The biotransformation of [14C]minaprine in man and five animals species. , 1981, Xenobiotica; the fate of foreign compounds in biological systems.